


Supplementary information

Supplementary Figure and Tables



Supplementary Figure S1. The participant flow diagram of this clinical study of third booster and blood sampling collection.

	BBIBP	AZD1222	p value	Result	BBIBP	BNT162b2	p value	Result	AZD1222	BNT162b2	p value	Result
n												
Total (%)	60 (100.00)	57 (100.00)			60 (100.00)	60 (100.00)			57 (100.00)	60 (100.00)		
Injection site pain	33 (55.00)	52 (91.23)	< 0.0001	Yes	33 (55.00)	59 (98.33)	< 0.0001	Yes	52 (91.23)	59 (98.33)	0.1079	No
Swelling	6 (10.00)	25 (43.86)	< 0.0001	Yes	6 (10.00)	25 (41.67)	0.0001	Yes	25 (43.86)	25 (41.67)	0.8531	No
Redness	4 (6.67)	18 (31.58)	0.0007	Yes	4 (6.67)	21 (35.00)	0.0002	Yes	18 (31.58)	21 (35.00)	0.8446	No
Fever	0 (0.00)	9 (15.79)	< 0.0001	Yes	0 (0.00)	5 (8.33)	0.0573	No	9 (15.79)	5 (8.33)	0.2615	No
Headache	10 (16.67)	41 (71.93)	< 0.0001	Yes	10 (16.67)	34 (56.67)	< 0.0001	Yes	41 (71.93)	34 (56.67)	0.1226	No
Myalgia	19 (31.67)	44 (77.19)	< 0.0001	Yes	19 (31.67)	44 (73.33)	< 0.0001	Yes	44 (77.19)	44 (73.33)	0.6729	No
Nausea	2 (3.33)	10 (17.54)	0.0142	Yes	2 (3.33)	11 (18.33)	0.0159	Yes	10 (17.54)	11 (18.33)	>0.9999	No
Vomiting	0 (0.00)	3 (5.26)	0.1125	No	0 (0.00)	5 (8.33)	0.0573	No	3 (5.26)	5 (8.33)	0.7175	No
Diarrhea	5 (8.33)	16 (28.07)	0.0074	Yes	5 (8.33)	10 (16.67)	0.2693	No	16 (28.07)	10 (16.67)	0.1825	No
Joint pain	3 (5.00)	23 (40.35)	< 0.0001	Yes	3 (5.00)	13 (21.67)	0.0136	Yes	23 (40.35)	13 (21.67)	0.0443	Yes

Chilling	5 (8.33)	32 (56.14)	< 0.0001	Yes	5 (8.33)	27 (45.00)	< 0.0001	Yes	32 (56.14)	27 (45.00)	0.2690	No
Dizziness	7 (11.67)	21 (36.84)	0.0021	Yes	7 (11.67)	23 (38.33)	0.0013	Yes	21 (36.84)	23 (38.33)	>0.9999	No

Supplementary Table S1 Statistic analysis of reactogenicity data of between the booster vaccines.

The Fisher's Exact Test was used to interpret the statistical analysis.

Supplementary Table S2. The data values from laboratory testing of participants who received the booster dose with BBIBP, AZD1222 or BNT162b2, which referred to graphic info displays.

	BBIBP	AZD1222	BNT162b2
Humoral responses			
Ig anti-RBD (U/mL)			
Day 0 (baseline), n	60	57	60
GMT (95% CI)	35.45 (25.8 - 48.71)	37.89 (27.39 - 52.41)	48.57 (36.54 - 64.58)
Day 14, n	60	56	59
GMT (95% CI)	1,073 (849.4 - 1,355)	9,865 (7,990 - 12,182)	20,787 (18,229 - 23,703)
Day 28, n	60	55	59
GMT (95% CI)	839.9 (674.1 - 1,047)	8,160 (6,635-10,035)	13,871 (11,993 - 16,043)
IgG anti-RBD (BAU/mL)			
Day 0 (baseline), n	60	57	60
GMT (95% CI)	42.76 (33.78 - 54.12)	41.13 (33.22 - 50.93)	48.99 (40.77 - 58.88)
Day 14, n	60	56	59
GMT (95% CI)	205.5 (167.0 - 253.0)	1,936 (1,597 - 2,346)	3,821 (3,306 - 4,416)
Day 28, n	60	55	59
GMT (95% CI)	164.1 (133.8 - 201.1)	1,736 (1,434 - 2,101)	2,584 (2,250 - 2,966)
IgG anti-N index (S/C)			
Day 0 (baseline), n	60	57	60
Median (IQR)	0.265 (0.140 - 1.130)	0.230 (0.095 - 0.810)	0.535 (0.170 - 1.078)
Day 14, n	60	56	59
Median (IQR)	2.970 (1.715 - 4.745)	0.205 (0.083 - 0.615)	0.51 (0.180 - 0.880)
Day 28, n	60	55	59
Median (IQR)	2.780 (1.513 - 4.643)	0.170 (0.070 - 0.400)	0.51 (0.230 - 0.880)
IgA anti-S1 ratio (S/C)			
Day 0 (baseline), n	20	20	20
Median (IQR)	0.685 (0.453 - 0.845)	0.455 (0.255 - 0.628)	0.675 (0.453 - 0.845)
Day 14, n	60	56	59
Median (IQR)	2.055 (1.073 - 4.383)	8.515 (5.23 - 9.00)	9.00 (9.00 - 9.00)
Day 28, n	60	55	59

Median (IQR)	1.300 (0.565 - 2.955)	7.450 (4.09 – 9.00)	9.00 (7.12– 9.00)
Neutralization assay			
sVNT-WT (%inhibition)			
Day 0 (baseline), n	10	10	10
Median (IQR)	20.9 (18.33 - 36.95)	35.15 (19.23 - 46.45)	40.25 (20.48 - 45.93)
Day 14, n	N/D	N/D	N/D
Median (IQR)			
Day 28, n	30	30	30
Median (IQR)	79.75 (62.33 - 89.93)	97.60 (97.20 - 97.80)	97.80 (97.68 - 97.90)
Neutralization assay			
sVNT-Alpha (%inhibition)			
Day 0 (baseline), n	10	10	10
Median (IQR)	9.25 (4.50 - 18.53)	17.30 (17.30 - 26.08)	19.45 (12.15 - 25.03)
Day 14, n	N/D	N/D	N/D
Median (IQR)			
Day 28, n	30	30	30
Median (IQR)	67.20 (51.10 - 81.80)	96.50 (94.58 - 97.33)	97.05 (97.05 - 97.53)
Neutralization assay			
sVNT-Beta (%inhibition)			
Day 0 (baseline), n	10	10	10
Median (IQR)	-3.80 ((-8.28) - 2.50)	-0.15 ((-19.93) - 10.68)	1.15 ((-10.95) - 7.50)
Day 14, n	N/D	N/D	N/D
Median (IQR)			
Day 28, n	30	30	30
Median (IQR)	50.55 (36.35 - 67.18)	91.85 (87.80 - 93.98)	93.30 (90.65 - 94.90)
Neutralization assay			
sVNT-Delta (%inhibition)			
Day 0 (baseline), n	10	10	10
Median (IQR)	24.40 (17.98 - 30.13)	30.95 (20.70 - 42.65)	27.40 (20.15 - 40.43)
Day 14, n	N/D	N/D	N/D
Median (IQR)			

Day 28, n	30	30	30
Median (IQR)	72.00 (53.75 - 86.93)	97.35 (96.45 - 97.73)	97.60 (97.18 - 97.80)
T-cell responses			
IFN-γ CD4⁺ (IU/mL)			
Day 0 (baseline), n	60	57	60
Median (IQR)	0.050 (0.020 - 0.140)	0.030 (0.000 - 0.145)	0.035 (0.000 - 0.128)
Day 14, n	60	56	58*
Median (IQR)	0.125 (0.053 - 0.453)	0.500 (0.188 - 1.173)	1.250 (0.430 - 3.698)
Day 28, n	60	55	59
Median (IQR)	0.085 (0.030 - 0.238)	0.260 (0.090 - 0.710)	0.790 (0.290 - 1.890)
IFN-γ CD4⁺ CD8⁺ (IU/mL)			
Day 0 (baseline), n	60	57	60
Median (IQR)	0.075 (0.030 - 0.258)	0.040 (0.010 - 0.210)	0.050 (0.010 - 0.208)
Day 14, n	60	56	58*
Median (IQR)	0.240 (0.060 - 0.615)	0.720 (0.325 - 1.690)	2.020 (0.538 - 4.993)
Day 28, n	60	55	59
Median (IQR)	0.155 (0.053 - 0.410)	0.470 (0.170 - 1.430)	1.260 (0.400 - 3.090)

N/D – do not determine.

* – one participant's sample is not adequate to evaluate QFN assay because we were unable to obtain the appropriate amount of heparinized blood.